HTL-0016878
- Generic Name
- HTL-0016878
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 284
- Registration Number
- NCT06963034
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 213
- Registration Number
- NCT05545111
- Locations
- 🇺🇸
Neurocrine Clinical site, Saint Louis, Missouri, United States
🇺🇸Neurocrine Clinical Site, Richardson, Texas, United States
Measurement of HTL0016878 in Cerebrospinal Fluid
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- Heptares Therapeutics Limited
- Target Recruit Count
- 16
- Registration Number
- NCT04849286
- Locations
- 🇬🇧
MAC Clinical Research, Manchester, United Kingdom
A Two Part Study to Assess Safety, PK, PD, and Food Effect of Oral HTL0016878
- First Posted Date
- 2017-08-09
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Heptares Therapeutics Limited
- Target Recruit Count
- 120
- Registration Number
- NCT03244228
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, Hammersmith, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath